Drug intelligence / Profile preview

DBM-1152A

Development stage: Phase 1
Lead developer: Joincare Pharmaceutical
Modality: Small Molecules
Administration: Inhalation

Overview

DBM-1152A (brand name: Shuobai) is a dual-target innovative drug developed by Joincare Pharmaceutical Group Industry Co., Ltd for the treatment of respiratory conditions, specifically asthma and chronic obstructive pulmonary disease (COPD). Formulated as an inhalation solution for nebulization, it is designed to act on two distinct molecular pathways relevant to airway management, although the specific biological targets have not been publicly disclosed. The drug is currently in Phase I clinical development, with studies evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses in healthy subjects.

Brand names: Shuobai

Targets

ADRB2 (β2)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on DBM-1152A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DBM-1152A.

Explore the full profile